Acute Treatment With Fingolimod Does Not Confer Long-Term Benefit in a Mouse Model of Intracerebral Haemorrhage

Acute Treatment With Fingolimod Does Not Confer Long-Term Benefit in a Mouse Model of Intracerebral Haemorrhage

Intracerebral haemorrhage (ICH) has no specific treatment, but accounts for up to 15% of all strokes and has the highest mortality. Fingolimod (FTY720) is an immunomodulator approved for the management of multiple sclerosis, with abundant evidence of efficacy in experimental ischemic stroke, and mor...

Full description

Bibliographic Details
Main Authors: Andrea C. Diaz Diaz, Jennifer A. Shearer, Kyle Malone, Christian Waeber
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Pharmacology
Subjects:
haemorrhagic stroke
immunomodulator
lymphocytes
sex differences
sphingosine 1-phosphate
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.613103/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.613103/full

Similar Items